AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
Clinical trial NCT02440568 · TERMINATED
Trial details
- NCT number
- NCT02440568
- Sponsor
- University of Illinois at Chicago
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-05
- Primary completion
- 2018-11-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.